Brief: Elicera Therapeutics Gets Approval To Initiate Clinical Phase I/II-Study CARMA

Elicera Therapeutics AB

09/02/2024 07:58

Feb 9 (Reuters) - Elicera Therapeutics AB  ELIC.ST :
    * RECEIVES APPROVAL TO INITIATE CLINICAL PHASE I/II-STUDY
CARMA
WITH CAR T-CELL THERAPY ELC-301 IN B-CELL LYMPHOMA
    * DOSE ESCALATION STUDY IS EXPECTED TO BE COMPLETED AND
REPORTED
IN SECOND HALF OF 2025
    * PHASE 2 IS EXPECTED TO BE COMPLETED AND REPORTED
APPROXIMATELY
6-12 MONTHS LATER THAN DOSE ESCALATION STUDY
    * FULL CARMA-STUDY IS EXPECTED TO BE COMPLETED AND REPORTED
IN
2027, AFTER A FOLLOW-UP PERIOD OF AT LEAST TWO YEARS.

Source text for Eikon:  ID:nWkr3LSbjr 
Further company coverage:  ELIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))